Abstract
Apoptosis-linked gene-2 (ALG-2) encodes a 22 kDa Ca2+-binding protein of the penta EF-hand family that is required for programmed cell death in response to various apoptotic agents. Here, we demonstrate that ALG-2 mRNA and protein are down-regulated in human uveal melanoma cells compared to their progenitor cells, normal melanocytes. The down regulation of ALG-2 may provide melanoma cells with a selective advantage. ALG-2 and its putative target molecule, Alix/AIP1, are localized primarily in the cytoplasm of melanocytes and melanoma cells independent of the intracellular Ca2+ concentration or the activation of apoptosis. Cross-linking and analytical centrifugation studies support a single-species dimer conformation of ALG-2, also independent of Ca2+ concentration. However, binding of Ca2+ to both EF-1 and EF-3 is necessary for ALG-2 interaction with Alix/AIP1 as demonstrated using surface plasmon resonance spectroscopy. Mutations in EF-5 result in reduced target interaction without alteration in Ca2+ affinity. The addition of N-terminal ALG-2 peptides, residues 1–22 or residues 7–17, does not alter the interaction of ALG-2 or an N-terminal deletion mutant of ALG-2 with Alix/AIP1, as might be expected from a model derived from the crystal structure of ALG-2. Fluorescence studies of ALG-2 demonstrate that an increase in surface hydrophobicity is primarily due to Ca2+ binding to EF-3, while Ca2+ binding to EF-1 has little effect on surface exposure of hydrophobic residues. Together, these data indicate that gross surface hydrophobicity changes are insufficient for target recognition.
Apoptosis-linked gene-2 (ALG-2) was first identified in a death-trap assay using a mouse T cell hybridoma model (1). These cells when transfected with an antisense ALG-2 expression vector were resistant to T cell receptor-mediated cell death and were partially protected from other agents that normally initiate programmed cell death such as Fas, staurosporine, actinomycin D, and C2-ceramide (1). More recent work suggests that ALG-2 might be involved in the apaf1-independent intrinsic apoptotic pathway activated as a result of endoplasmic reticulum (ER) stress (2).
ALG-2 contains five putative EF-hand sequences and is a member of the family of PEF1 (penta-EF-hand) proteins that includes the calpain small subunit, sorcin, and grancalcin (3). In ALG-2, EF-1 and EF-3 are considered the high-affinity Ca2+-binding sites, while one low-affinity site was also detected, which may correspond to EF-5 (4). Studies using recombinant mouse ALG-2 indicated that the solubility of the protein in the presence of Ca2+ is enhanced when the N-terminal hydrophobic non-PEF region was deleted, suggesting that this region might be exposed as a result of Ca2+ binding, leading to protein aggregation (3-5). Cross-linking studies using the recombinant protein and deletion mutants (3) also showed that at elevated protein concentrations, ALG-2 formed a weak homodimer even in the absence of Ca2+. The crystal structure of a truncated form of ALG-2 identified the C-terminal domain, consisting of the fifth EF-hand, as the region involved in the formation of the dimer complex (Figure 1) (4). The crystal structure was obtained for Ca2+-loaded ALG-2 following digestion with elastase to remove residues 1–20. A decapeptide, consisting of multiple glycine and proline residues and likely originating from a portion of the digested N-terminus of ALG-2, was found bound to a hydrophobic cleft between the N- and C-terminal halves of ALG-2. Binding of Ca2+ purportedly exposes the hydrophobic cleft, allowing binding of its N-terminal region to the newly formed pocket; this then supposedly induces a substantial conformational change in ALG-2, triggering target recognition and binding.
Two groups (6, 7) have independently identified the target protein for ALG-2, Alix or AIP1. Alix/AIP1 is a cytoplasmic protein ∼98 kDa in size, containing a proline-rich C-terminal region encompassing several Src homology domain 3 (SH3) binding motifs. This region was shown to interact with SETA (SH3 domain expressed in tumorigenic astrocytes) (8), whereby Alix/AIP1 could mediate UV light-induced cell death in astrocytes. Alix/AIP1 has also been implicated in multivesicular sorting mediated by the interactions of the N-terminal region of the protein with CHMP4b (9), while the C-terminal region is associated with ALG-2 interactions. It has been proposed that Alix/AIP1 could form a molecular link between endosomal sorting and cell death pathways (10).
The coimmunoprecipitation of ALG-2 with Alix/AIP1 requires Ca2+ concentration in the submicromolar range (7). Two isoforms of ALG-2 have been reported in mouse tissues; one form lacks two amino acids (G121 and F122), has different Ca2+-binding properties from the longer version, and does not interact with Alix/AIP1 (11). In Dictyostelium, two isoforms of ALG-2 also were identified, displaying differences in the length of their N-terminal non-PEF regions. Only the isoform with the shorter N-terminal region could interact with Alix/AIP1 (12).
Here, we demonstrate that in uveal melanoma, the most common primary tumor originating in the adult eye, melanoma cells down-regulate ALG-2, thereby imbuing some selective advantage upon these cells. In an attempt to understand the effect of Ca2+ on the structure and interactions of ALG-2, we have determined the conditions for dimer formation, the cellular localization of ALG-2 and Alix/AIP1, the roles of the N-terminal region and the functional EF hands of ALG-2 on Ca2+-induced conformational changes, and their effect on subsequent interactions with Alix/AIP1. These studies are critical for understanding how Ca2+ initiates recognition between a member of the family of PEF proteins and its target.
MATERIALS AND METHODS
Cell Culture. Cells were cultured as previously described (13). Briefly, Mel290 cells were established from a biopsy of human uveal melanoma and maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 10 mM HEPES, penicillin (100 U/ml), streptomycin (100 μg/mL), and 0.1% amphotericin B. Normal uveal melanocytes were obtained from human donor eyes and kept in short-term cultures according to published procedures (14).
RNase Protection Assay. ALG-2 transcript levels were compared in uveal melanocytes and Mel290 cells by RNase protection assay using 250 base antisense ALG-2 riboprobes and a 177 base antisense glyceraldehyde-3-phosphate dehydrogenase (GAPDH) riboprobe as an internal standard. Methods were described previously (13).
Expression and Purification of Full-Length ALG-2 and dNALG-2. ALG-2 exons were amplified using the primers 5′-CCG CGA ACA TAT GGC CGC CTA CTC TTA CCG-3′ and 5′-GCG GCG GAT CCG TTG TGC TGC TCT TCA CGA GA-3′ from cDNA derived from uveal melanocytes and cloned into pCR2.1 using a TA cloning kit (Invitrogen). The insert containing the correct sequence was isolated and purified after restriction digestion with NdeI and BamHI and then cloned into the pET3a expression system. Recombinant protein was expressed in Escherichia coli strain BL21(DE3) cells. Cells in LB media containing 100 μg/mL ampicillin were grown to an OD600 of 0.6 and then induced with 0.4 mM IPTG and grown overnight at 25 °C. ALG-2 protein was purified from bacterial pellets using methods previously described (3). ALG-2 partitioned to the soluble fraction after extraction of the post-French press bacterial pellet with 10 mM Tris, pH 7.5, containing 1 mM EDTA. ALG-2 was further enriched and purified using an ion-exchange FPLC column (Mono Q, Pharmacia) and NaCl gradient for elution. Protein was quantified spectrophotometrically. The N-terminal deletion mutant construct of ALG-2 (dNAlg-2), corresponding to residues 21–191, was obtained by PCR amplification of purified pET3aAlg-2 plasmid using the primers 5′-GCC CAT ATG GCG CTG CCG GAC CAG AGC-3′ and 5′-GCG GCG GAT CCG TTG TGC TGC TCT TCA CGA GA-3′. The PCR product was cloned, expressed, and purified using the same methods as for full-length ALG-2.
Expression and Purification of Alix/AIP1. The N-terminal GST (glutathione S-transferase)-tagged Alix/AIP1 clone was obtained from Dr. R. Sadoul (Universitè Joseph-Fourier, Pavillon de Neurologie, Centre Hospitalier Universitaire de Grenoble). The protein was expressed in bacteria, the GST-tag was cleaved using the Pre-scission protease (Amersham) according to the manufacturer's recommendations, and Alix/AIP1 was purified by affinity chromatography as described previously (12).
Site-Directed Mutagenesis of ALG-2. The ALG-2 mutants E114D, E47D, D169A, and dF122 were made using the Quickchange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. Complementary primers used were as follows: for E114D, 5′-ATGATCGATAAGAACGACCTGAAGCAGGCCCTC-3′ and 5′-GAGGGCCTGCTTCAGGTCGTTCTTATCGATCAT-3′; for E47D, 5′-GTGATATCAGACA CCGACCTTCAGCAAGCTCTC-3′ and 5′-GAGAGCTTGCTGAAGGTCGGTGTCTGATATCAC-3′; for D169A, 5′-ATATTCAGACGTTACGCCACGGATCAGGACGGC-3′ and 5′-GCCGTCCTGATCCGTGGCGTAAC GTCTGAATAT-3′; for dF122, 5′-CTCTCAGGTGGCTACCGGCTCTCTGACCAGTTC-3′ and 5′-GA ACTGGTCAGAGAGCCGGTAGCCACCTGAGAG-3′. The two complementary primers used were extended during temperature cycling using Pfu Turbo DNA polymerase with pET3aALG-2 as the template. Following DpnI digestion of the parental cDNA, the preparation was transformed into XL1-blue supercompetent cells. Cycling parameters used were 30 s at 95 °C and 12 cycles of 30 s at 95 °C, 1 min at 55 °C, 10 min at 68 °C. Plasmids from sequenced clones were then transformed into BL21pLysS(DE3) and expressed and purified using the same methods used for full-length ALG-2.
Preparation of Affinity-Purified Antibodies. Antibodies to recombinant full-length ALG-2 were raised in rabbits following published procedures (15). The immunoreactive serum was purified on an affinity column whereby ALG-2 was immobilized on CNBr-activated Sepharose beads (Pharmacia). Polyclonal rabbit antibodies to a peptide derived from the Alix/AIP1 sequence, LDEEATDNDLRAK, were purified similarly. Antibodies to ALG-2 protein were also raised in rats, and the antiserum was used directly for the detection of ALG-2.
Immunoblotting Analysis. Proteins were resolved using 15% SDS-polyacrylamide gel electrophoresis and transferred to poly(vinylidene difluoride) membranes (Immobilon-P, Millipore). Blots were blocked with 5% BSA and 5% nonfat dry milk in TBST, pH 8.0. Primary antibody incubations were carried out for 1 h at room temperature followed by 1 h incubation with an HRP-conjugated anti-immunoglobulin (Jackson Immunoresearch Lab.). Bands were visualized using the enhanced chemiluminescence system (ECL, Amersham) and exposure to X-ray film.
Immunocytochemistry. Staining of fixed cells was carried out as previously described (16). Rat anti-ALG-2 and rabbit anti-Alix/AIP1 were used as primary antibodies followed by Texas red conjugated anti-mouse (Amersham) and FITC conjugated anti-rabbit (Vector Lab.) secondary antibodies. Cells were viewed with a Zeiss Axiophot microscope.
Cellular Cross-Linking of ALG-2. Mel290 cells (5 × 106) were incubated for 30 min at room temperature in Hank's balanced salt solution containing the amino-reactive, cleavable cross-linker dithiobis[succinimidylpropionate] (1 mM DSP, Pierce) after 15 min pretreatment with either 10 μM thapsigargin or 1 mM EDTA at room temperature. Cells were scraped and lysed in 10 mM Tris, 10 mM NaCl, pH 7.5, containing protease inhibitors. Lysates were analyzed by immunoblotting under reducing and nonreducing conditions and probed with anti-ALG-2 antibodies.
Sedimentation Equilibrium of ALG-2 and dNALG-2. Protein samples at 5, 10, and 20 μM prepared in Chelex-treated 10 mM Tris, pH 7.5 containing 150 mM NaCl (with or without 1 mM EDTA or containing 5 μM CaCl2) were analyzed in a Beckman Optima XL-A analytical centrifuge. Double sector charcoal-filled Epon centerpieces were used with path lengths of 12 mm. Buffer was used as reference in one sector, and 105 μL of sample was in the other. The concentration gradients were recorded at 280 nm every 2–4 h until the gradients became superimposable (after ∼12–16 h). Initial absorbance values were recorded at 3000 rpm. Equilibrium data were collected at 9000, 12 000, 16 000, and 22 000 rpm at 20 °C. Reversibility was checked at 12 000 rpm by reducing the speed after equilibrium had been reached at 22 000 rpm. At the end of the run, sample depletion was carried out at 42 000 rpm to obtain baseline absorbance values for each cell. The molecular weight and partial specific volume were calculated from the amino acid sequence to be 21 454 and 0.727, respectively, for full-length ALG-2 (determined to be residues 3–189 by mass spectrometric analysis) and 20 067 and 0.727 for dNALG-2 (residues 21–191). The extinction coefficient for ALG-2 was determined and found to match the reported value of 39 200 M−1 cm−1. The buffer density was measured with an Anton Paar DMA5000 density meter and found to be 1.003 g/mL at 20 °C.
A program written for Igor Pro (Wavemetrics Inc., Lake Oswego, OR) by Darrell R. McCaslin (Biophysics Instrumentation Facility, UW Madison) was used for the analysis of the sedimentation equilibrium data. Prior to analysis, all data sets were corrected for baseline absorbance as determined from the values obtained after protein depletion. All data sets (three concentrations each at four speeds) were fit simultaneously to a single species (monomer) and an oligomeric model.
Flow Dialysis. Metal-free protein samples were prepared by incubating the concentrated proteins with 100 μM EGTA followed by Sephadex G-25 gel filtration in a buffer containing 50 mM Tris-HCl, pH 7.5, and 150 mM KCl. The protein concentration was measured spectrophotometrically using a molar extinction coefficient at 278 nm of 39 670 M−1 cm−1. Ca2+ binding was measured at 25 °C by flow dialysis using 20–25 μM protein (17). Experiments were carried out in the presence of 0.5% Tween 20 to prevent protein precipitation as previously published (18). Detergent was present in both the stationary protein compartment and the perfusate. Treatment of the raw data and evaluation of the intrinsic metal-binding constants have been described elsewhere (19).
Surface Plasmon Resonance. Real-time binding analysis was performed at 25 °C using an SPR biosensor, BIAcore system (Biacore, Uppsala, Sweden), and methods previously described (12, 20). The amount of immobilized Alix/AIP1 corresponded to 14 000 resonance units. Running buffer for protein interaction contained 20 mM Tris, 150 mM NaCl, pH 7.5, and 0.005% surfactant P-20 (BIACORE). Flow rate was maintained at 20 μL/min. Reference sensorgrams for subtraction of bulk refractive index background were obtained by running protein over an unimmobilized flow cell. Surfaces were regenerated by injecting 100 μL of 1 mM EDTA. Association studies were carried out with 60 μL of sample followed by 120 s of dissociation either with buffer containing Ca2+ (COINJECT program) or with running buffer (KINJECT program).
TNS Fluorescence Measurements. Fluorescence measurements were carried out using 2-(p-toluidino)naphthalene-6-sulfonate (TNS) fluorescence enhancement. All fluorescence measurements were recorded at room temperature with a Shimadzu RF-5301PC spectrofluorometer in 20 mM Tris, 150 mM NaCl, pH 7.5. Typically 500 μL of buffer containing 2 μM protein and 10 μM TNS with or without added Ca2+ or EDTA was used. Excitation wavelength was set at 340 nm and emission spectra were measured from 350 to 550 nm. Fluorescence intensity values were measured at 436 nm.
RESULTS
Expression of ALG-2 in Uveal Melanoma. Initial subtractive hybridization experiments indicated that the expression of ALG-2 is diminished in Mel290, a uveal melanoma cell line, compared with uveal melanocytes (UM), the normal progenitor cells (data not shown). To verify these findings, ALG-2 mRNA levels were compared by RNAse protection assay using an antisense probe specific for ALG-2 (Figure 2A). Lower amounts of ALG-2 mRNA were detected in the Mel290 cells. These results extended to protein levels as well, determined by immunoblotting of whole cell extracts (Figure 2B). Mel290 cells therefore down-regulate the Ca2+-binding, proapoptotic protein ALG-2, consistent with findings from the original subtractive hybridization studies.
Localization of ALG-2 and Alix/AlP1. The cytoplasmic localization of ALG-2 was previously demonstrated in 3DO cells, a mouse T cell hybridoma line (1), while in a subpopulation of Jurkat cells and certain lung and breast cancer cells ALG-2 showed nuclear staining (21). ALG-2 also was localized to the nuclei of transiently transfected BOSC23 cells (22). To clarify the cellular localization of ALG-2 and its putative target protein Alix/AIP1, UM and Mel290 cells were analyzed by double-label immunocytochemistry. In UM cells (Figure 3A) and Mel290 cells (Figure 3C), ALG-2 localized predominantly to the cytoplasm with additional perinuclear staining. Alix/AIP1 demonstrated the same subcellular distribution as ALG-2 in colocalization studies of UM and melanoma cells (Figure 3B,D, respectively).
A subset of UM and Mel290 cells also displayed nuclear staining for both ALG-2 and Alix/AIP1. Costaining with Hoechst dye demonstrated that ALG-2 redistributes throughout the cell during metaphase, following break-down of the nuclear membrane, except to regions occupied by condensed chromosomes (Figure 3E,F).
Other studies have suggested that the distribution of ALG-2 may depend on the Ca2+ concentration. To test this proposal in UM and Mel290 cells, we fixed and immunostained cells for the distribution of ALG-2 in the presence of added Ca2+ or EDTA (Figure 4A,B). ALG-2 remained cytoplasmic under both conditions in both cell types. Thapsigargin and ionomycin, known Ca2+-mobilizing agents, and apoptotic agents, such as staurosporin, were used to determine whether elevation of intracellular Ca2+ or induction of apoptosis would cause the redistribution of ALG-2. None of these conditions affected the localization of ALG-2 (data not shown).
Dimerization of ALG-2. To determine whether ALG-2 exists as a dimer at cellular concentrations under high and low Ca2+ concentration, Mel290 cells were treated with the cell-permeable, reversible cross-linker DSP after preincubation with either thapsigargin to increase intracellular free Ca2+ concentration or EDTA. The cells were then lysed, and proteins were separated by gel electrophoresis. Following treatment with thapsigargin, bands containing ALG-2 were identified by Western blotting using anti-ALG-2 antibodies (Figure 5A, lane 1). A 42 kDa band was observed under nonreducing conditions. The size of the cross-linked product suggests the formation of dimer. In the presence of reducing agent, β-mercaptoethanol, the cross-linker was cleaved, and ALG-2 assumed the mobility of a 21 kDa protein, corresponding to the monomer (Figure 5A, lane 2). Similar results were obtained with cells treated with EDTA (data not shown). These findings suggest that ALG-2 forms dimers at cellular concentrations, and dimer formation is unaffected by changes in the intracellular Ca2+ concentration.
To determine whether ALG-2 forms dimers in the absence of Ca2+ and other cellular components, recombinant ALG-2 was expressed. Analytical centrifugation studies were conducted with the purified protein in the presence of EDTA. The average molecular weight calculated from the equilibrium data obtained from three different protein concentrations (5–20μM) at four speeds suggest that ALG-2 exists predominantly as a dimer (expected = 42 908, observed = 38 910) at the concentrations used for the analysis (Figure 5B). The lower concentration samples and those at higher speeds had lower average molecular weights suggesting increased monomer content. On the basis of the dissociation constant obtained from the simulations, at protein concentrations less than 1 μM, ALG-2 exists in equilibrium between monomer and dimer.
In the presence of Ca2+, purified ALG-2 tends to form aggregates and precipitate at concentrations required for analytical centrifugation. Deletion of the N-terminal region of ALG-2 improves its solubility in the presence of Ca2+ (5). dNALG-2, the truncated form of ALG-2 comprised of amino acids 21–191, therefore, was cloned and expressed. Analytical centrifugation experiments both in the presence (5 μM Ca2+) and absence (1 mM EDTA) of Ca2+ were then conducted. Observed average molecular weights were 40 505 and 39 626, respectively (expected dimer weight = 40 128). Results from these experiments support a single-species dimer model independent of Ca2+ (Figure 5C).
Interaction with Alix/AIP1. Surface plasmon resonance (SPR) has been used successfully to look at the interaction between Dictyostelium discoideum ALG-2 and murine Alix/ AIP1 (12). We examined the in vitro interaction between human ALG-2 and Alix/AIP1 to determine regions of interaction and the Ca2+ dependency of their interaction. Purified Alix/AIP1 was immobilized on the surface of a CM5 chip (Biacore). ALG-2 interaction with Alix/AIP1 was compared in the presence and absence of Ca2+ (Figure 6A). No interaction was observed in the presence of EDTA, and the response was similar to the control flow cell containing no immobilized Alix/AIP1. However, in the presence of Ca2+, there was an increased response to ALG-2 in the flow cell containing Alix/AIP1. Removal of both protein and Ca2+resulted in the rapid dissociation of the complex as can be seen in Figure 6A. The relative response, measured at the plateau of the sensorgrams, increased as a function of both protein concentration (Figure 6B) and Ca2+ concentration (Figure 6C) until saturation was reached at ∼1000 nM ALG-2 in the presence of 50 μM Ca2+ or 400 nM ALG-2 in the presence of 100 μM Ca2+.
Deletion of F122, a residue absent in a noninteracting ALG-2 isoform identified in mice (18), markedly reduced the affinity for Alix/AIP1 and served as a negative control (Figure 8A).
These data collectively demonstrate that the interaction between ALG-2 and Alix/AIP1 is specific and depends on Ca2+ concentration.
Effect of Ca2+ Binding to Functional EF Hands. To determine which Ca2+-binding sites are essential for the interaction of ALG-2 with Alix/AIP1, site-directed mutagenesis was performed to replace critical Ca2+-coordinating residues within the reported functional EF hands of ALG-2 (4, 5, 18). Mutants were generated with single amino acid substitutions at glutamate residues in the consensus sequences within EF-1 and EF-3, converting them to aspartate residues (E47D and E114D, respectively). As shown in other EF-hand-type calcium-binding proteins, replacement of glutamate, contributing two oxygens to the coordination of Ca2, with a shorter aspartate increases the rate of Ca2+ dissociation and lowers overall affinity without affecting electrostatic charge requirements for loop stability (23, 24). In addition to these reported high-affinity sites, the aspartate in EF-5, the purported low-affinity site, was replaced with an alanine (D169A). CD measurements of mutants when compared to ALG-2 show superimposable molar ellipticity spectra indicating that mutants retained their secondary structure (data not shown).
Flow dialysis confirmed that wild-type ALG-2 possesses two high-affinity Ca2+-binding sites and one low-affinity site (Figure 7), as published previously (18). In contrast, the E47D mutant possesses only one high-affinity site, suggesting that EF-1 is a normal high-affinity site in ALG-2. The substitution of glutamate for aspartate in position 12 of the first Ca2+-chelating loop corresponding to EF-1 does not eliminate but lowers the affinity for Ca2+ by a factor of 30 (K2′(ALG-2) = 4.0 × 105; K2′(E47D) = 1.3 × 104). The affinities of the remaining two sites are not × significantly altered by this mutation. The mutation E114D leads to more profound alterations in the Ca2+-binding properties of ALG-2. Only two binding sites can be titrated (Figure 7), and the affinities of these sites are lower than the high-affinity sites in the wild-type protein (K1′(ALG-2) = 5.3 × 105, K2′(ALG-2) = 4.0 × 105; K1′(E114D) = 8.0 × 104, K2′(E114D) = 3.0 × 104). Thus it seems that this mutation simultaneously weakens Ca2+ binding to EF-1 and EF-3 and abolishes the low-affinity site. The binding curve of E114D shows negative cooperativity, and we suppose that EF-3 displays the lower intrinsic affinity constant of the two (3.0 × 104). At the concentrations of calcium (10–50 μM) used in subsequent experiments, the curves in Figure 7 demonstrate that wild-type ALG-2 binds 2 mol of Ca2+ per mole of protein, while the E47D and E114D mutants bind only 1 mol of Ca2+ per mole of protein. The Ca2+-binding properties of the mutant D169A are quite similar to that of the wild-type ALG-2 (Figure 7).
These mutants were then compared with ALG-2 for their ability to interact with Alix/AIP1 (Figure 8B). At Ca2+ concentration concentrations of 50 μM, corresponding to the two high-affinity sites being occupied in ALG-2 and one site in E47D and E114D (Figure 7), the mutants lacked significant interaction with Alix/AIP1, comparable to responses using the unimmobilized flow cell. D169A had a lower response in the presence of Ca2+ than full-length ALG-2 but more than the baseline signal obtained for the EF-1 and EF-3 mutants. Experiments could not be conducted at higher concentrations of calcium in an attempt to occupy additional calcium-binding sites in mutant forms of ALG-2 owing to protein precipitation that occurs at elevated levels of calcium in the absence of detergent.
Effect of the N-Terminal Non-PEF Region on Interactions with Alix/AIP1. Studies of the crystal structure of a truncated form of ALG-2 (residues 21–191) suggested that the binding of the N-terminal region of ALG-2 to a hydrophobic pocket occurs upon Ca2+ binding to EF-1 and EF-3 (Figure 1) (4). The folding of the N-terminal region into the hydrophobic pocket then causes a hinge effect, opening the molecule for target recognition. This model would suggest that the absence of the N-terminal region might prevent or attenuate the interaction of ALG-2 with the target molecule. To further test the model, the interaction of the N-terminal deletion mutant (dNALG-2) with Alix/AIP1 was studied using SPR. In the presence of Ca2+, the response obtained with dNALG-2 was comparable to full-length ALG-2 for immobilized Alix/AIP1. Further, the addition of peptides corresponding to residues 7–17 (Figure 8C) and the deleted N-terminal portion, residues 1–22 (data not shown), to either dNALG-2 or ALG-2 had no effect on the interaction with Alix/AIP1. These results suggest that regions other than the N-terminal portion of ALG-2 interact with Alix/AIP1, and the N-terminal region does not enhance the binding of ALG-2 to Alix/AIP1.
Ca2+-Induced Conformational Changes in ALG-2. The Ca2+-induced conformational changes in ALG-2 and mutants were studied by examining fluorescence emission spectra in the presence of TNS. These experiments were carried out to investigate whether changes in surface hydrophobicity correlated with affinity for the target molecule, Alix/AIP1, as determined by SPR. In the presence of Ca2+, ALG-2 showed a marked increase in fluorescence, similar to results obtained with mouse ALG-2 (5). Deletion of the N-terminal region had little effect on this Ca2+-induced fluorescence change (Figure 9A). Both full-length and truncated forms of ALG-2 showed maximum fluorescence intensity at 40 μM Ca2+ and saturation at higher Ca2+ concentration. Based on the flow data, this concentration is suggestive of only the high-affinity sites being occupied. As with the interaction with Alix/AIP1, there was no consequence of addition of the N-terminal peptides (residues 7–17 or 1–21) to the Ca2+-induced TNS fluorescence changes of dNALG-2 or full-length ALG-2 (data not shown). These results correlate with the results from SPR studies where deletion of the N-terminal region had little effect on the interaction with Alix/AIP1.
SPR results clearly indicate that interference with Ca2+ binding at both EF-1 and EF-3 significantly compromises the interaction with Alix/AIP1 and that the D169A mutation also has a moderate effect. TNS fluorescence experiments were carried out with the mutants of ALG-2, E47D (EF-1), E114D (EF-3), and D169A (EF-5) in the absence (1 mM EDTA) and presence of 60 μM Ca2+. Mutation in EF-3 completely abrogated the Ca2+-induced hydrophobicity changes detectable by TNS fluorescence (Figure 9B), correlating with the lack of interaction of this mutant with Alix/AIP1. In contrast, the EF-1 mutation only slightly reduced the TNS fluorescence signal upon the addition of Ca2+. The D169A mutation resulted in an intermediate Ca2+-induced fluorescence change. Results suggest that the most significant conformational change, detectable by TNS fluorescence changes, arises from Ca2+ binding to EF-3.
DISCUSSION
In addition to unregulated cell growth, disruption of apoptosis may be important during tumor growth and metastasis. More malignant tumor cells may be selected owing to their higher expression of antiapoptotic factors or their down regulation of proapoptotic genes (25, 26). Ca2+ plays a significant role in apoptosis and mediates at least a portion of its function through the action of Ca2+-binding proteins (27). In uveal melanoma, we demonstrate the differential expression of ALG-2, a gene identified as a Ca2+-dependent regulator of apoptosis. Mel290 cells derived from a human tumor were found to express lower levels of ALG-2 mRNA and protein than normal uveal melanocytes. The down regulation of ALG-2 suggests one way by which these cells may achieve a selective advantage, by interfering with Ca2+-mediated apoptotic signals and thereby enhancing cell survival.
Krebs et al. (28) compared the expression of ALG-2 in cell extracts obtained from biopsies of normal and malignant tissues from the same patient. Unlike uveal melanoma, a significant increase in ALG-2 expression in the cancerous tissues from different lung and breast tumors was reported. Immunohistochemistry of the lung carcinomas in those studies showed intense ALG-2 staining largely localized to the nuclei of tumor cells. However, some commercial anti-ALG-2 antibodies have been found by this and other laboratories (29, 30) to recognize a protein of the same size as ALG-2 but to be unable to recognize the recombinant protein. We therefore generated polyclonal antibodies to purified and sequenced human ALG-2 and used them for immunoblotting and immunohistochemical analyses. ALG-2 was found to localize to the cytoplasm of UM and melanoma cells independent of Ca2+ concentration or activation of programmed cell death. Treatment of these cells with thapsigargin, a drug known to release calcium from intracellular stores and cause cell death through ER stress with potential ALG-2 involvement (2), did not result in any change in localization of ALG-2. The contrast in findings between our studies and others (21, 28, 29) may be due to the different cancer cell types being examined or the fidelity of the antibodies used in the studies (30).
Various biochemical and structural approaches have been used to characterize different ALG-2 analogues (3, 4, 12, 18, 20, 31) . As with other members of this family of Ca2+-binding proteins, ALG-2 exists as a dimer in solution (32, 33). From our studies, dimer formation is independent of Ca2+ and is unaffected by the deletion of the N-terminal region. The role of the N-terminal non-EF-hand region of ALG-2 might vary between species. The ALG-2 isoforms in Dictyostelium were found to require the N-terminal region for both dimer formation and interaction (12). Both ALG-2 forms had longer N-terminal regions than mouse or human ALG-2. In the case of human ALG-2, deletion of the N-terminal region improved the solubility of the protein in the presence of Ca2+. The deletion, however, did not affect dimer formation, consistent with the involvement of the C-terminal region in this process based on the crystal structure (Figure 1) (4). Deletion of the N-terminal region also did not significantly affect the Ca2+-induced conformational change as observed by TNS fluorescence measurements. Ca2+-dependent interaction with Alix/AIP1 for full-length ALG-2 and dNALG-2 also were comparable. The N-terminal region of ALG-2 therefore might have more significant consequences in terms of its interactions with target molecules other than Alix/AIP1 in other cell types.
On the basis of the crystal structure of Ca2+-bound, elastase-digested ALG-2, it was suggested that the binding of Ca2+ resulted in the formation of a hydrophobic pocket, occupied by the N-terminal region of ALG-2 and causing a hinge-like effect, opening the molecule for target binding (4). TNS fluorescence and Alix/AIP1 interaction studies presented here show no difference between ALG-2 and dNALG-2 with or without the addition of exogenous peptides corresponding to the cocrystallized decapeptide derived from elastase treatment of ALG-2, as well as the entire N-terminal peptide, suggesting that at least in the case of Alix/AIP1, the interaction mechanism does not involve the N-terminal region of human ALG-2.
Of the five EF-hands in ALG-2, EF-1 and EF-3 have been identified as the high-affinity Ca2+-binding sites (4, 5, 18). The location of the low-affinity site is less well established. In the crystal structure, a third Ca2+ is bound to EF-5 (4), potentially due to artificially high concentrations of protein and Ca2+. Site-directed mutagenesis was used in the studies presented here to specifically alter a critical residue required for Ca2+ coordination in each of these EF hands. Flow dialysis data of the E47D mutant confirm that EF-1 comprises one of the high-affinity Ca2+-binding sites and the mutation effectively eliminates Ca2+ binding. In contrast, the concomitant decrease of both high-affinity sites in the E114D mutant is unexpected and points to a structural role of this residue. Flow dialysis data of E114D indicate a direct effect on EF-3, the second high-affinity Ca2+-binding site, and an indirect effect on EF-1. The relatively small difference in the binding curves of D169A and wild-type ALG-2, together with the fact that the low-affinity site is not abolished, suggest that the precise location of the latter site remains unresolved. The crystal structure of ALG-2 shows two Ca2+ ions bound to EF-3; perhaps the E114D mutation disables the binding of one ion but not the other. If the extra Ca2+ in EF-3 corresponds to the low-affinity site rather than EF-5, then this might explain the ineffectiveness of the D169A mutation in abolishing the low-affinity Ca2+-binding site. The physiological relevance of the low-affinity site, however, is unclear since occupancy requires millimolar Ca2+, unexpected in the cytosol.
Interestingly, the E47D and E114D mutations both resulted in loss of interaction with Alix/AIP1. The D169A mutation, despite little change in Ca2+ affinity, also affected the interaction though not as significantly as the EF-1 and EF-3 mutants. The crystal structure (Figure 1) and studies on other members of the PEF family (34-38) indicate that this region is important for dimer formation. Residues from the F-helix of EF-5 also contribute to the hydrophobic pocket, potentially involved in target recognition. The reduced interaction might therefore result from the mutation in EF-5 impacting on other structural aspects important to the interaction of ALG-2 with Alix/AIP1 rather than influencing Ca2+-binding. This further supports a model whereby EF-1 and EF-3 are the functional Ca2+-binding sites in ALG-2 and both sites have to be occupied for substantive interaction with Alix/AIP1.
The shorter aspartate in the E114D mutant may reorient the C-terminal α-helix of EF-3, reshape the microenvironment around F122, and reduce hydrophobic exposure. TNS fluorescence results support this conclusion, whereby Ca2+ binding to EF-3 is essential for the conformational change resulting in the increased exposure of hydrophobic surfaces. Since both EF-1 and EF-3 are required for the interaction of ALG-2 with Alix/AIP1, Ca2+ binding to EF-1 might result in angle changes within the protein that are necessary for target recognition but do not significantly alter surface hydrophobicity.
In summary, we demonstrate that ALG-2 exists as a dimer in the cytoplasm of cells, independent of Ca2+ concentration, and undergoes conformational changes, including the increased exposure of hydrophobic surfaces through Ca2+ binding to EF-1 and EF-3. These conformational changes allow for target recognition and binding of Alix/AIP1. Based on the expression of putative target molecules in different cell types and physiological conditions, ALG-2 can mediate pathways involved in apoptosis (1), cell proliferation (28, 29), or both.
In uveal melanoma cells, reduced expression of ALG-2 likely favors cell survival through diminished apoptosis. Most current therapies are nonspecific and can result in considerable damage to normal tissue and have little impact on mortality, reaching more than 50% in high-risk melanoma patients (39-41). The characterization of biochemical pathways that can modulate cell death may lead to molecular therapies selectively targeting tumor cells.
ACKNOWLEDGMENT
We would like to thank Dr. R. Stenkamp for his help with Figure 1 and Dr. D. R. McCaslin for his help with the analysis of the analytical centrifugation data.
Footnotes
This work was supported by NIH Grants EY12768 and EY13705 (A.S.P.), EY08061 (K.P.), and EY06603 and EY14239 (J.W.C.) and the Swiss National Science Foundation 31-65071.01 (J.C.), as well as grants from the Retina Research Foundation, Research to Prevent Blindness Inc. (RPB), the University of Wisconsin Comprehensive Cancer Center, and the E. K. Bishop Foundation. L.S. is a recipient of the Cremer Scholarship. A.S.P. is a Jules and Doris Stein RPB Professor.
Abbreviations: ER, endoplasmic reticulum; PEF, penta-EF-hand; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IPTG, isopropyl-β-d-thiogalactopyranoside; GST, glutathione S-transferase; CNBr, cyanogen bromide; TBST, Tris-buffered saline with Tween-20; HRP, horse-radish peroxidase; FITC, fluorescein isothiocyanate conjugate; DSP, dithiobis[succinimidylpropionate]; SPR, surface plasmon resonance; TNS, 2-(p-toluidino)naphthalene-6-sulfonate; UM, uveal melanocytes; CD, circular dichroism.
Contributor Information
John W. Crabb, Cole Eye Institute and Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195.
Krzysztof Palczewski, Departments of Ophthalmology, Pharmacology, and Chemistry, University of Washington, Seattle, Washington 98195.
REFERENCES
- 1.Vito P, Lacana E, D′Adamio L. Interfering with apoptosis: Ca(2+)-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science. 1996;271:521–525. doi: 10.1126/science.271.5248.521. [DOI] [PubMed] [Google Scholar]
- 2.Rao RV, Poksay KS, Castro-Obregon S, Schilling B, Row RH, del Rio G, Gibson BW, Ellerby HM, Bredesen DE. Molecular components of a cell death pathway activated by endoplasmic reticulum stress. J. Biol. Chem. 2004;279:177–187. doi: 10.1074/jbc.M304490200. [DOI] [PubMed] [Google Scholar]
- 3.Lo KWH, Zhang Q, Li M, Zhang MJ. Apoptosis-linked gene product ALG-2 is a new member of the calpain small subunit subfamily of Ca2+-binding proteins. Biochemistry. 1999;38:7498–7508. doi: 10.1021/bi990034n. [DOI] [PubMed] [Google Scholar]
- 4.Jia J, Tarabykina S, Hansen C, Berchtold M, Cygler M. Structure of apoptosis-linked protein ALG-2: insights into Ca2+-induced changes in penta-EF-hand proteins. Structure (Cambridge) 2001;9:267–275. doi: 10.1016/s0969-2126(01)00585-8. [DOI] [PubMed] [Google Scholar]
- 5.Maki M, Yamaguchi K, Kitaura Y, Satoh H, Hitomi K. Calcium-induced exposure of a hydrophobic surface of mouse ALG-2, which is a member of the penta-EF-hand protein family. J. Biochem. (Tokyo) 1998;124:1170–1177. doi: 10.1093/oxfordjournals.jbchem.a022235. [DOI] [PubMed] [Google Scholar]
- 6.Missotten M, Nichols A, Rieger K, Sadoul R. Alix, a novel mouse protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 (ALG-2) protein. Cell Death Differ. 1999;6:124–129. doi: 10.1038/sj.cdd.4400456. [DOI] [PubMed] [Google Scholar]
- 7.Vito P, Pellegrini L, Guiet C, D′Adamio L. Cloning of AIP1, a novel protein that associates with the apoptosis-linked gene ALG-2 in a Ca2+-dependent reaction. J. Biol. Chem. 1999;274:1533–1540. doi: 10.1074/jbc.274.3.1533. [DOI] [PubMed] [Google Scholar]
- 8.Chen B, Borinstein SC, Gillis J, Sykes VW, Bogler O. The glioma-associated protein SETA interacts with AIP1/Alix and ALG-2 and modulates apoptosis in astrocytes. J. Biol. Chem. 2000;275:19275–19281. doi: 10.1074/jbc.M908994199. [DOI] [PubMed] [Google Scholar]
- 9.Katoh K, Shibata H, Suzuki H, Nara A, Ishidoh K, Kominami E, Yoshimori T, Maki M. The ALG-2-interacting protein Alix associates with CHMP4b, a human homologue of yeast Snf7 that is involved in multivesicular body sorting. J. Biol. Chem. 2003;278:39104–39113. doi: 10.1074/jbc.M301604200. [DOI] [PubMed] [Google Scholar]
- 10.Trioulier Y, Torch S, Blot B, Cristina N, Chatellard-Causse C, Verna JM, Sadoul R. Alix, a protein regulating endosomal trafficking, is involved in neuronal death. J. Biol. Chem. 2004;279:2046–2052. doi: 10.1074/jbc.M309243200. [DOI] [PubMed] [Google Scholar]
- 11.Tarabykina S, Moller AL, Durussel I, Cox J, Berchtold MW. Two forms of the apoptosis-linked protein ALG-2 with different Ca2+ affinities and target recognition. J. Biol. Chem. 2000;275:10514–10518. doi: 10.1074/jbc.275.14.10514. [DOI] [PubMed] [Google Scholar]
- 12.Aubry L, Mattei S, Blot B, Sadoul R, Satre M, Klein G. Biochemical characterization of two analogues of the apoptosis-linked gene 2 protein in Dictyostelium discoideum and interaction with a physiological partner in mammals, murine Alix. J. Biol. Chem. 2002;277:21947–21954. doi: 10.1074/jbc.M201718200. [DOI] [PubMed] [Google Scholar]
- 13.Walker TM, Van Ginkel PR, Gee RL, Ahmadi H, Subramanian L, Ksander BR, Meisner LF, Albert DM, Polans AS. Expression of angiogenic factors Cyr61 and tissue factor in uveal melanoma. Arch. Ophthalmol. 2002;120:1719–1725. doi: 10.1001/archopht.120.12.1719. [DOI] [PubMed] [Google Scholar]
- 14.Hu DN, McCormick SA, Orlow SJ, Rosemblat S, Lin AY. Regulation of melanogenesis by human uveal melanocytes in vitro. Exp. Eye Res. 1997;64:397–404. doi: 10.1006/exer.1996.0223. [DOI] [PubMed] [Google Scholar]
- 15.Polans AS, Palczewski K, Asson-Batres MA, Ohguro H, Witkowska D, Haley TL, Baizer L, Crabb JW. Purification and primary structure of Capl, an S-100-related calcium-binding protein isolated from bovine retina. J. Biol. Chem. 1994;269:6233–6240. [PubMed] [Google Scholar]
- 16.van Ginkel PR, Gee RL, Walker TM, Hu DN, Heizmann CW, Polans AS. The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim. Biophys. Acta Mol. Cell Res. 1998;1448:290–297. doi: 10.1016/s0167-4889(98)00133-5. [DOI] [PubMed] [Google Scholar]
- 17.Colowick SP, Womack FC. Binding of diffusible molecules by macromolecules: rapid measurement by rate of dialysis. J. Biol. Chem. 1969;244:774–777. [PubMed] [Google Scholar]
- 18.Tarabykina S, Moller AL, Durussel I, Cox J, Berchtold MW. Two forms of the apoptosis-linked protein ALG-2 with different Ca(2+) affinities and target recognition. J. Biol. Chem. 2000;275:10514–10518. doi: 10.1074/jbc.275.14.10514. [DOI] [PubMed] [Google Scholar]
- 19.Cox JA. In: Guidebook to the Calcium-binding Proteins. Celio MR, Paul ST, Schwaller B, editors. Oxford University Press; Oxford, U.K: 1996. pp. 1–12. [Google Scholar]
- 20.Satoh H, Shibata H, Nakano Y, Kitaura Y, Maki M. ALG-2 interacts with the amino-terminal domain of annexin XI in a Ca2+-dependent manner. Biochem. Biophys. Res. Commun. 2002;291:1166–1172. doi: 10.1006/bbrc.2002.6600. [DOI] [PubMed] [Google Scholar]
- 21.Krebs J, Klemenz R. The ALG-2/AIP-complex, a modulator at the interface between cell proliferation and cell death? A hypothesis. Biochim. Biophys. Acta. 2000;1498:153–161. doi: 10.1016/s0167-4889(00)00091-4. [DOI] [PubMed] [Google Scholar]
- 22.Hwang IS, Jung YS, Kim E. Interaction of ALG-2 with ASK1 influences ASK1 localization and subsequent JNK activation. FEBS Lett. 2002;529:183–187. doi: 10.1016/s0014-5793(02)03329-x. [DOI] [PubMed] [Google Scholar]
- 23.Palczewski K, Polans AS, Baehr W, Ames JB. Ca2+-binding proteins in the retina: structure, function, and the etiology of human visual diseases. BioEssays. 2000;22:337–350. doi: 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
- 24.Babu A, Su H, Ryu Y, Gulati J. Determination of residue specificity in the EF-hand of troponin C for Ca2+ coordination, by genetic engineering. J. Biol. Chem. 1992;267:15469–15474. [PubMed] [Google Scholar]
- 25.Green DR, Evan GI. A matter of life and death. Cancer Cell. 2002;1:19–30. doi: 10.1016/s1535-6108(02)00024-7. [DOI] [PubMed] [Google Scholar]
- 26.Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001;409:207–211. doi: 10.1038/35051606. [DOI] [PubMed] [Google Scholar]
- 27.Hajnoczky G, Davies E, Madesh M. Calcium signaling and apoptosis. Biochem. Biophys. Res. Commun. 2003;304:445–454. doi: 10.1016/s0006-291x(03)00616-8. [DOI] [PubMed] [Google Scholar]
- 28.Krebs J, Saremaslani P, Caduff R. ALG-2: a Ca2+-binding modulator protein involved in cell proliferation and in cell death. Biochim. Biophys. Acta. 2002;1600:68–73. doi: 10.1016/s1570-9639(02)00446-6. [DOI] [PubMed] [Google Scholar]
- 29.la Cour JM, Mollerup J, Winding P, Tarabykina S, Sehested M, Berchtold MW. Up-regulation of ALG-2 in hepatomas and lung cancer tissue. Am. J. Pathol. 2003;163:81–89. doi: 10.1016/S0002-9440(10)63632-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Mollerup J, Krogh TN, Nielsen PF, Berchtold MW. Properties of the co-chaperone protein p23 erroneously attributed to ALG-2 (apoptosis-linked gene 2) FEBS Lett. 2003;555:478–482. doi: 10.1016/s0014-5793(03)01310-3. [DOI] [PubMed] [Google Scholar]
- 31.Kitaura Y, Matsumoto S, Satoh H, Hitomi K, Maki M. Peflin and ALG-2, members of the penta-EF-hand protein family, form a heterodimer that dissociates in a Ca2+-dependent manner. J. Biol. Chem. 2001;276:14053–14058. doi: 10.1074/jbc.M008649200. [DOI] [PubMed] [Google Scholar]
- 32.Teahan CG, Totty NF, Segal AW. Isolation and characterization of grancalcin, a novel 28 kDa EF-hand calcium-binding protein from human neutrophils. Biochem. J. 1992;286(Part 2):549–554. doi: 10.1042/bj2860549. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Hamada H, Okochi E, Oh-hara T, Tsuruo T. Purification of the Mr 22,000 calcium-binding protein (sorcin) associated with multidrug resistance and its detection with monoclonal antibodies. Cancer Res. 1988;48:3173–3178. [PubMed] [Google Scholar]
- 34.Jia J, Han Q, Borregaard N, Lollike K, Cygler M. Crystal structure of human grancalcin, a member of the penta-EF-hand protein family. J. Mol. Biol. 2000;300:1271–1281. doi: 10.1006/jmbi.2000.3925. [DOI] [PubMed] [Google Scholar]
- 35.Kitaura Y, Satoh H, Takahashi H, Shibata H, Maki M. Both ALG-2 and peflin, penta-EF-hand (PEF) proteins, are stabilized by dimerization through their fifth EF-hand regions. Arch. Biochem. Biophys. 2002;399:12–18. doi: 10.1006/abbi.2001.2736. [DOI] [PubMed] [Google Scholar]
- 36.Hansen C, Tarabykina S, la Cour JM, Lollike K, Berchtold MW. The PEF family proteins sorcin and grancalcin interact in vivo and in vitro. FEBS Lett. 2003;545:151–154. doi: 10.1016/s0014-5793(03)00518-0. [DOI] [PubMed] [Google Scholar]
- 37.Maki M, Kitaura Y, Satoh H, Ohkouchi S, Shibata H. Structures, functions and molecular evolution of the penta-EF-hand Ca2+-binding proteins. Biochim. Biophys. Acta. 2002;1600:51–60. doi: 10.1016/s1570-9639(02)00444-2. [DOI] [PubMed] [Google Scholar]
- 38.Todd B, Moore D, Deivanayagam CC, Lin GD, Chattopadhyay D, Maki M, Wang KK, Narayana SV. A structural model for the inhibition of calpain by calpastatin: crystal structures of the native domain VI of calpain and its complexes with calpastatin peptide and a small molecule inhibitor. J. Mol. Biol. 2003;328:131–146. doi: 10.1016/s0022-2836(03)00274-2. [DOI] [PubMed] [Google Scholar]
- 39.Seddon JM, Gragoudas ES, Albert DM, Hsieh CC, Polivogianis L, Friedenberg GR. Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. Am. J. Ophthalmol. 1985;99:282–290. doi: 10.1016/0002-9394(85)90357-5. [DOI] [PubMed] [Google Scholar]
- 40.Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72:2219–2223. doi: 10.1002/1097-0142(19931001)72:7<2219::aid-cncr2820720725>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
- 41.Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, Benjamin RS. Treatment of uveal melanoma metastatic to the liver – A review of the M D Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76:1665–1670. doi: 10.1002/1097-0142(19951101)76:9<1665::aid-cncr2820760925>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]